FDA 483 - Cipla Ltd.

Cipla Ltd., an Active Pharmaceutical Ingredient (API) manufacturer in Bangalore, India, was inspected by the FDA from May 26-30, 2025. The inspection identified critical observations concerning the firm's quality management system and adherence to current Good Manufacturing Practices.

The primary issue noted was the company's failure to adequately extend investigations into related quality events. Specifically, Cipla Ltd. did not sufficiently trend and evaluate 19 deviations from 2021-2025, which included electrical, electronic, human error, and equipment malfunctions, sometimes leading to data loss or batch failures. Additionally, the firm had 39 failed batches during this period, with process optimization pending for certain products. Concerns were also raised about the accuracy and reproducibility of QC Laboratory test methods, noting a lack of method robustness for some assays and instances where incorrect test methods were used due to incomplete software programming after updates.

These findings necessitate that Cipla Ltd. implement robust corrective and preventive actions to enhance its investigation processes, improve manufacturing controls, and ensure the reliability of its laboratory testing to comply with regulatory standards.